Highlights of ESC HF 2021 - AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting
1 trek • 0 pemutaran • 0 favorit
Highlights of ESC HF 2021 - AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting
Demms Dezzy
0:003:32
Knowledge
Episode
1
Highlights of ESC HF 2021 - AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting
Demms Dezzy